CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
Active, not recruiting · NCT04667663 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-04-13 | NCT04667663 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Cancer Trials Ireland | 26 |
| Janssen Pharmaceuticals | 24 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beaumont Hospital | Dublin | Ireland | 24 |
| Cork University Hospital | Cork | Ireland | 34 |
| Galway University Hospital | Galway | Ireland | 10 |